In Difficult Times For AAV Gene Therapies, AbbVie Boosts Regenxbio’s Ambitions

Wet AMD Is Challenging Target

 
• By Andrew McConaghie
  
Regenxbio
Regenxbio has set out an ambitious goal of five gene therapies in pivotal trials or on the market by 2025 • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D